

---

## [Monographs Affected by Revision to <601> Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests](#)

**Type of Posting:** Notice of Intent to Revise

**Posting Date:** 02–Oct–2020

**Targeted Official Date:** 01–May–2021

**Expert Committee:** Various

In accordance with the 2020–2025 Rules and Procedures of the Council of Experts, this is to provide notice that USP and its Expert Committees, as applicable, intend to revise multiple monographs in response to the revision of General Chapter <601> *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests*.

General Chapter <601> was proposed for comment in *Pharmacopeial Forum* 45(6) and will appear in *USP–NF* 2021, *Issue 1*. USP has identified other documentary standards that reference General Chapter <601> and thus require revision to modify these references. These references will be updated when the General Chapter appears in *USP–NF* 2021, *Issue 1*. A list of the monographs that will be modified can be found [here](#).

All modifications will become official on May 1, 2021, to coincide with the official date of revised General Chapter <601>.

Please also see the Compendial Notice: [New Revision Markup for Reference Changes in USP–NF](#) for details on the revision markup used to identify the reference updates.

Interested stakeholders are encouraged to alert USP staff to any impact they may recognize related to the update of those monographs.

Should you have any questions or comments, please contact Kahkashan Zaidi, Principal Scientific Liaison Team Leader, ([kxz@usp.org](mailto:kxz@usp.org)), or the affected monograph's liaisons.

